Amber L. Mosley

Biochemistry, Genetics and Molecular Biology · Indiana University

RNA Research and Splicing Ubiquitin and proteasome pathways RNA modifications and cancer RNA and protein synthesis mechanisms vaccines and immunoinformatics approaches

Publications

199

Citations

4,450

Est. group size

Recurring co-author estimate

Active years

Publishing since 2002

Publication cadence

Publications per year over the last 10 years — averaging 21.4/year recently

Recent publications

Dual CDK4/6–PI3K/mTOR inhibition reinforces cytostatic programs and tumor control in preclinical models of primary and metastatic osteosarcoma
Neoplasia · 2026
Deletion of SPI1 in microglia exacerbates amyloid pathology by impairing microglial response in Alzheimer’s disease models
Neuron · 2026
Abstract 6483: Convergent CDK4/6 and PI3K/mTOR pathway hyperactivation defines a targetable axis in osteosarcoma across RB1-proficient and RB1-deficient contexts
Cancer Research · 2026
Comparison of methods for isolation of extracellular vesicles from bronchoalveolar lavage fluid
Extracellular Vesicles and Circulating Nucleic Acids · 2026
A CAMKK2-UBR4-19S Proteasome Axis Regulates Chondrocyte Proteostasis and SOX9 Stability
bioRxiv (Cold Spring Harbor Laboratory) · 2026
Figure S4 from Immunoproteasome Activation Expands the MHC Class I Immunopeptidome, Unmasks Neoantigens, and Enhances T-cell Anti-Myeloma Activity
2026
Figure S5 from Immunoproteasome Activation Expands the MHC Class I Immunopeptidome, Unmasks Neoantigens, and Enhances T-cell Anti-Myeloma Activity
2026
Figure S7 from Immunoproteasome Activation Expands the MHC Class I Immunopeptidome, Unmasks Neoantigens, and Enhances T-cell Anti-Myeloma Activity
2026
Figure S9 from Immunoproteasome Activation Expands the MHC Class I Immunopeptidome, Unmasks Neoantigens, and Enhances T-cell Anti-Myeloma Activity
2026
Supplementary Table 2 from Immunoproteasome Activation Expands the MHC Class I Immunopeptidome, Unmasks Neoantigens, and Enhances T-cell Anti-Myeloma Activity
2026
Figure S1 from Immunoproteasome Activation Expands the MHC Class I Immunopeptidome, Unmasks Neoantigens, and Enhances T-cell Anti-Myeloma Activity
2026
Figure S3 from Immunoproteasome Activation Expands the MHC Class I Immunopeptidome, Unmasks Neoantigens, and Enhances T-cell Anti-Myeloma Activity
2026
Figure S8 from Immunoproteasome Activation Expands the MHC Class I Immunopeptidome, Unmasks Neoantigens, and Enhances T-cell Anti-Myeloma Activity
2026
Supplementary Table 1 from Immunoproteasome Activation Expands the MHC Class I Immunopeptidome, Unmasks Neoantigens, and Enhances T-cell Anti-Myeloma Activity
2026
Figure S2 from Immunoproteasome Activation Expands the MHC Class I Immunopeptidome, Unmasks Neoantigens, and Enhances T-cell Anti-Myeloma Activity
2026

Publishes in

bioRxiv (Cold Spring Harbor Laboratory)×25
Cancer Research×9
Journal of Biological Chemistry×5
PMC×5
Alzheimer s & Dementia×4

This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.

Last updated Jul 9, 2026.

Claim or correct this profile